Pancreatic beta cell autoantigens

Pancreatic beta cell autoantigens are a group of endogenous proteins expressed by the insulin-producing beta cells of the pancreas that become the primary targets of an aberrant autoimmune response in Type 1 Diabetes (T1D) (DiMeglio et al., 2018, Lancet). Key antigens within this group include insulin, glutamic acid decarboxylase 65 (GAD65), insulinoma-associated protein 2 (IA-2), and zinc transporter 8 (ZnT8) (Wenzlau et al., 2007, PNAS). These proteins play essential roles in beta cell physiology, such as hormone production, zinc transport, and enzymatic activity (Insel et al., 2015, Diabetes Care). In genetically susceptible individuals, the loss of immune tolerance leads to the activation of autoreactive T-cells and B-cells against these specific proteins, resulting in the progressive destruction of beta cell mass (Peakman, 2021, Clin Exp Immunol). The detection of autoantibodies against these antigens serves as the gold standard for the clinical diagnosis and risk prediction of T1D (Pihoker et al., 2005, Diabetes). Therapeutic strategies targeting these antigens include antigen-specific immunotherapies, such as GAD65 vaccines (Diamyd) or proinsulin peptides, which aim to induce regulatory T-cell responses and preserve residual insulin-secretory capacity (Herold et al., 2019, NEJM). While broad immunomodulators like Teplizumab target the T-cells reacting to these antigens, specific antigen-based therapies seek to restore immune tolerance without systemic immunosuppression.

Other names

Islet cell antigensBeta cell autoantigensT1D autoantigensPancreatic islet antigens

Induction of antigen-specific immune tolerance, modulation of autoreactive T-cell activity, and preservation of pancreatic beta cell mass.